Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 22, Issue 18, Pages -Publisher
MDPI
DOI: 10.3390/ijms22189677
Keywords
beta-thalassemia; anemia; immunological disturbances
Ask authors/readers for more resources
Thalassemia is a chronic disease caused by mutations in the beta-globin gene, leading to chronic anemia. Patients with beta-thalassemia display variable clinical severity and enhanced susceptibility to infections due to immune deficiency caused by the disease itself and therapies. Immune deficiency in beta-thalassemia patients is associated with various biological processes, including abnormalities in innate immune system components.
Thalassemia, a chronic disease with chronic anemia, is caused by mutations in the beta-globin gene, leading to reduced levels or complete deficiency of beta-globin chain synthesis. Patients with beta-thalassemia display variable clinical severity which ranges from asymptomatic features to severe transfusion-dependent anemia and complications in multiple organs. They not only are at increased risk of blood-borne infections resulting from multiple transfusions, but they also show enhanced susceptibility to infections as a consequence of coexistent immune deficiency. Enhanced susceptibility to infections in beta-thalassemia patients is associated with the interplay of several complex biological processes. beta-thalassemia-related abnormalities of the innate immune system include decreased levels of complement, properdin, and lysozyme, reduced absorption and phagocytic ability of polymorphonuclear neutrophils, disturbed chemotaxis, and altered intracellular metabolism processes. According to available literature data, immunological abnormalities observed in patients with thalassemia can be caused by both the disease itself as well as therapies. The most important factors promoting such alterations involve iron overload, phenotypical and functional abnormalities of immune system cells resulting from chronic inflammation oxidative stress, multiple blood transfusion, iron chelation therapy, and splenectomy. Unravelling the mechanisms underlying immune deficiency in beta-thalassemia patients may enable the designing of appropriate therapies for this group of patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available